BNTC

Benitec Biopharma Inc. [BNTC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BNTC Stock Summary

Top BNTC Correlated Resources

BNTC


Top 10 Correlated ETFs

BNTC


Top 10 Correlated Stocks

BNTC


In the News

08:05 28 Mar 2024 BNTC

Benitec Biopharma to Present at the OPMD International Conference

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

11:21 28 Mar 2024 BNTC

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

03:58 28 Mar 2024 BNTC

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

08:10 28 Mar 2024 BNTC

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.

08:05 28 Mar 2024 BNTC

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study.

09:55 28 Mar 2024 BNTC

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions.

04:44 28 Mar 2024 BNTC

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C.

10:20 28 Mar 2024 BNTC

BNTC Stock Price Increased 190.28%: Why It Happened

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.

05:03 28 Mar 2024 BNTC

Benitec BioPharma Shares Rally: Technical Levels To Watch

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check.

09:57 28 Mar 2024 BNTC

What Will the Stock Market Do Today? 3 Big Stories to Watch.

What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.

BNTC Financial details

Company Rating
Sell
Market Cap
12.83M
Income
-21.87M
Revenue
61K
Book val./share
6
Cash/share
7.91
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.34
Forward P/E
-1.36
PEG
0.05
P/S
108.73
P/B
0.31
P/C
0.65
P/FCF
-0.44
Quick Ratio
5.72
Current Ratio
5.83
Debt / Equity
0.03
LT Debt / Equity
0.01
-
-
EPS (TTM)
-10.94
EPS next Y
-3.77
EPS next Q
-1.14
EPS this Y
-63.44%
EPS next Y
-65.52%
EPS next 5Y
-106.93%
EPS last 5Y
NAN%
Revenue last 5Y
-63.33%
Revenue Q/Q
-
EPS Q/Q
-4.35%
-
-
-
-
SMA20
30.59%
SMA50
62.3%
SMA100
45.98%
Inst Own
0.03%
Inst Trans
0%
ROA
-75%
ROE
-224%
ROC
-0.9%
Gross Margin
241%
Oper. Margin
-27167%
Profit Margin
-27049%
Payout
-
Shs Outstand
2.59M
Shs Float
2.35M
-
-
-
-
Target Price
-
52W Range
1.86-9.01
52W High
-43%
52W Low
+413%
RSI
60.76
Rel Volume
0.27
Avg Volume
14.92K
Volume
3.99K
Perf Week
-0.19%
Perf Month
80%
Perf Quarter
72.73%
Perf Half Y
62.86%
-
-
-
-
Beta
1.021
-
-
Volatility
0.13%, 0.81%
Prev Close
3.43%
Price
5.13
Change
1.58%

BNTC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric History 2019-06-302020-06-302021-06-302022-06-30 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
224.551.610.230.150.05
Net income per share
56.89-138.19-54.54-38.62-14.12
Operating cash flow per share
95.05-125.44-50.79-33.08-13
Free cash flow per share
87.04-127.02-51.66-33.1-13
Cash per share
313.95163.1878.248.451.79
Book value per share
328.79170.4379.1960.15
Tangible book value per share
328.79170.4379.1960.15
Share holders equity per share
328.79170.4379.1960.15
Interest debt per share
06.740.821.750.43
Market cap
13.82M8.08M18.26M9.48M5.63M
Enterprise value
-1.88M-1.32M-1.3M6.23M3.71M
P/E ratio
4.82-0.97-1.32-0.51-0.29
Price to sales ratio
1.2283.27309.41129.8575.02
POCF ratio
2.88-1.07-1.42-0.6-0.31
PFCF ratio
3.15-1.06-1.4-0.6-0.31
P/B Ratio
0.830.790.913.2927.85
PTB ratio
0.830.790.913.2927.85
EV to sales
-0.17-13.59-22.0485.3249.44
Enterprise value over EBITDA
-0.870.170.1-0.35-0.2
EV to operating cash flow
-0.390.170.1-0.39-0.21
EV to free cash flow
-0.430.170.1-0.39-0.21
Earnings yield
0.21-1.03-0.75-1.96-3.48
Free cash flow yield
0.32-0.94-0.72-1.68-3.2
Debt to equity
00.040.010.282.77
Debt to assets
00.030.010.140.13
Net debt to EBITDA
-7.271.21.470.180.1
Current ratio
7.19.5115.051.90.94
Interest coverage
002.27K-557.94-578.21
Income quality
1.840.910.920.870.92
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.5957.39110.3791.0485.09
Research and developement to revenue
0.1930.94118.98154.41170.32
Intangibles to total assets
00000
Capex to operating cash flow
-0.080.010.0200
Capex to revenue
-0.04-0.98-3.75-0.18-0.01
Capex to depreciation
-2.55-0.25-0.52-0.030
Stock based compensation to revenue
0.082.4410.7511.926.03
Graham number
648.75727.96311.7572.186.8
ROIC
0.16-0.75-0.66-4.04-14.46
Return on tangible assets
0.15-0.72-0.64-3.11-4.38
Graham Net
299.3149.3572.92.02-1.25
Working capital
16.09M9.67M19.24M2.29M-249K
Tangible asset value
16.57M10.24M20.01M2.88M202K
Net current asset value
16.09M9.46M19.24M1.73M-533K
Invested capital
00.040.010.282.77
Average receivables
2.83M1.3M42K14K29K
Average payables
1.46M1.39M581K1.38M1.51M
Average inventory
0.5474K474K0.96.5K
Days sales outstanding
81.68222.01154.6615267.67
Days payables outstanding
2.13K383.972.61K76.24K1.09K
Days of inventory on hand
01.29K00.0712.45
Receivables turnover
4.471.642.3624.331.36
Payables turnover
0.170.950.1400.33
Inventory turnover
426.51K0.2805K29.31
ROE
0.17-0.81-0.69-6.44-96.84
Capex per share
-8-1.58-0.87-0.030

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q2

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.03000
Net income per share
-3.27-2.71-2.83-2.76-2.64
Operating cash flow per share
-3.67-2.45-2.49-2.12-2.08
Free cash flow per share
-3.67-2.45-2.49-2.12-2.08
Cash per share
6.623.981.5111.997.91
Book value per share
5.652.860.1210.346
Tangible book value per share
5.652.860.1210.346
Share holders equity per share
5.652.860.1210.346
Interest debt per share
0.440.380.340.220.17
Market cap
4.6M5.88M6.68M6.52M8.32M
Enterprise value
-5.25M-51.96K4.76M-18.85M-11.63M
P/E ratio
-0.22-0.33-0.36-0.27-0.31
Price to sales ratio
328.52108.82954.100
POCF ratio
-0.79-1.46-1.63-1.42-1.55
PFCF ratio
-0.79-1.46-1.63-1.42-1.55
P/B Ratio
0.511.2533.060.290.54
PTB ratio
0.511.2533.060.290.54
EV to sales
-375.19-0.96680.100
Enterprise value over EBITDA
0.960.01-1.053.211.69
EV to operating cash flow
0.90.01-1.164.122.17
EV to free cash flow
0.90.01-1.164.122.17
Earnings yield
-1.13-0.76-0.7-0.91-0.82
Free cash flow yield
-1.27-0.69-0.61-0.7-0.64
Debt to equity
0.080.132.770.020.03
Debt to assets
0.060.080.130.020.02
Net debt to EBITDA
1.811.40.424.322.91
Current ratio
4.412.350.945.833.62
Interest coverage
-623.33-620.14-568.75979-1.15K
Income quality
1.080.920.880.770.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
133.0722.74195.8600
Research and developement to revenue
268.6458.65455.1400
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00-0.1400
Capex to depreciation
00-0.0100
Stock based compensation to revenue
-3.431.3118.1400
Graham number
20.4113.212.825.3418.88
ROIC
-0.52-0.74-3.39-0.25-0.42
Return on tangible assets
-0.44-0.54-1.04-0.22-0.32
Graham Net
4.821.88-1.069.815.64
Working capital
8.49M4.24M-249K21.88M15.05M
Tangible asset value
8.99M4.71M202K22.31M15.47M
Net current asset value
8.06M3.89M-533K21.67M14.91M
Invested capital
0.080.132.770.020.03
Average receivables
35.5K62K55.5K54K53K
Average payables
569.5K583K887.5K1.33M2.07M
Average inventory
0.157K13.5K13K13.5K
Days sales outstanding
437.1493.33707.1400
Days payables outstanding
1.17K1.79K1.22K-1.3K235.71K
Days of inventory on hand
039.3813.93-11.041.26K
Receivables turnover
0.210.960.1300
Payables turnover
0.080.050.07-0.070
Inventory turnover
-205K2.296.46-8.150.07
ROE
-0.58-0.95-23.07-0.27-0.44
Capex per share
00000

BNTC Frequently Asked Questions

What is Benitec Biopharma Inc. stock symbol ?

Benitec Biopharma Inc. is a US stock , located in Hayward of Ca and trading under the symbol BNTC

What is Benitec Biopharma Inc. stock quote today ?

Benitec Biopharma Inc. stock price is $5.13 today.

Is Benitec Biopharma Inc. stock public?

Yes, Benitec Biopharma Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap